Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Procopio

Showing results (121-130 of 289) with videos related to

Pageof 29
Sort By:
Tumori|October 28, 2009
Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakesEmilio Bajetta, Laura Catena, Monika Ducceschi, et al.
Tumori|October 7, 2024
Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacyAlessandro Rametta, Paolo Ambrosini, Chiara Cavalli, et al.
Clinical Genitourinary Cancer|January 31, 2024
Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or PazopanibMartina Catalano, Ugo De Giorgi, Davide Bimbatti, et al.
Oncology|September 28, 2021
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)Umberto Basso, Giuseppe Procopio, Giuseppe Fornarini, et al.
Expert Review of Anticancer Therapy|August 8, 2020
The emerging role of PARP inhibitors in prostate cancerMarco Stellato, Valentina Guadalupi, Pierangela Sepe, et al.
Biomedicines|October 27, 2022
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell CarcinomaMartina Catalano, Ugo De Giorgi, Marco Maruzzo, et al.
American Journal of Clinical Oncology|September 5, 2020
Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)Pierangela Sepe, Antonia Martinetti, Alessia Mennitto, et al.
Tumori|November 6, 2020
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinomaRaffaele Ratta, Elena Verzoni, Alessia Mennitto, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 17, 2020
Patient associations and clinical oncology research: how much does a patient's voice really matter?Veronica Franchina, Celeste Cagnazzo, Alessandro Di Costanzo, et al.
European Urology Oncology|July 24, 2019
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, et al.
Pageof 29

Showing results (121-130 of 289) with videos related to

Sort By:
Pageof 29
Tumori|October 28, 2009
Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakesEmilio Bajetta, Laura Catena, Monika Ducceschi, et al.
Tumori|October 7, 2024
Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacyAlessandro Rametta, Paolo Ambrosini, Chiara Cavalli, et al.
Clinical Genitourinary Cancer|January 31, 2024
Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or PazopanibMartina Catalano, Ugo De Giorgi, Davide Bimbatti, et al.
Oncology|September 28, 2021
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)Umberto Basso, Giuseppe Procopio, Giuseppe Fornarini, et al.
Expert Review of Anticancer Therapy|August 8, 2020
The emerging role of PARP inhibitors in prostate cancerMarco Stellato, Valentina Guadalupi, Pierangela Sepe, et al.
Biomedicines|October 27, 2022
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell CarcinomaMartina Catalano, Ugo De Giorgi, Marco Maruzzo, et al.
American Journal of Clinical Oncology|September 5, 2020
Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)Pierangela Sepe, Antonia Martinetti, Alessia Mennitto, et al.
Tumori|November 6, 2020
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinomaRaffaele Ratta, Elena Verzoni, Alessia Mennitto, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 17, 2020
Patient associations and clinical oncology research: how much does a patient's voice really matter?Veronica Franchina, Celeste Cagnazzo, Alessandro Di Costanzo, et al.
European Urology Oncology|July 24, 2019
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, et al.
Pageof 29